Updated:
CEL SCI CORP
CEL SCI CORP was founded to advance the development of Multikine, a leukocyte interleukin injection intended as a first-line treatment for locally...
CEL SCI CORP
CEL SCI CORP was founded to advance the development of Multikine, a leukocyte interleukin injection intended as a first-line treatment for locally advanced squamous cell carcinoma of the head and neck. The firm has no publicly disclosed founding date, named principals, or headquarters location beyond a probable US corporate address. The company has never generated revenue from product sales. Its primary capital allocation has been directed toward clinical trials, regulatory filings, and manufacturing process development for Multikine. The firm does not report a strategic asset allocation across traditional asset classes such as equities, fixed income, or real estate, nor does it disclose any portfolio companies or third-party fund commitments. CEL SCI CORP operates as a microcap public entity (OTC ticker symbol: CELS) with a market capitalization typically under $50 million. There is no evidence of a team with investment professionals, multiple offices, or adjacent vehicles such as a philanthropic foundation or operating businesses. The firm has not reported any recent operational events beyond routine regulatory filings with the SEC. The structural differentiator is the firm's identity as a single-product biotechnology company rather than a capital allocator. Unlike a conventional family office or asset manager, CEL SCI CORP does not manage third-party capital, deploy funds across a portfolio, or generate income from investments. Its sole purpose is to bring a single drug candidate through clinical development to potential commercialization.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
null
City
null
Corporate office
null
Sector focus
Frequently asked questions
What is the status of Multikine, CEL SCI CORP's lead drug candidate?
Multikine completed a global Phase 3 clinical trial (the Pivotal Trial) in patients with advanced squamous cell carcinoma of the head and neck, but as of public record, it has not received marketing approval from the FDA or any other regulatory body. The company has submitted the trial results to the FDA and continues to seek a path to approval.
Does CEL SCI CORP behave as a typical biotech company or a family office?
The firm operates as a development-stage biotechnology company, not as a family office or asset manager. It does not manage or deploy investment capital into other entities or assets, and it has no disclosed portfolio companies, fund investments, or wealth management operations.
Has CEL SCI CORP ever generated revenue from product sales?
According to public filings, CEL SCI CORP has not recorded any revenue from product sales. The company has funded operations through equity offerings and debt financing, with the bulk of expenditure directed toward clinical and regulatory activities for Multikine.
Where is CEL SCI CORP incorporated and headquartered?
The firm is incorporated in the United States but does not publicly disclose a specific headquarters address. Its SEC filings list a business address in Rockville, Maryland, though the company may have a nominal rather than operational office presence.
What is the firm's market cap and stock ticker?
CEL SCI CORP trades on the OTC Markets under ticker symbol CELS. Its market capitalization is typically below $50 million, reflecting its microcap status and pre-commercial stage.
Does the company have any other drug candidates or pipeline programs?
Public disclosures indicate that CEL SCI CORP has concentrated all resources on Multikine. There is no publicly reported pipeline of additional drug candidates or research programs beyond this single asset.
How does CEL SCI CORP's governance structure differ from a typical investment firm?
The company is governed by a board of directors and officers typical of a public corporation, not by investment professionals or family office principals. The CEO and executive leadership have backgrounds in clinical development and regulatory affairs rather than in capital management or asset allocation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: